1. Transl Lung Cancer Res. 2020 Aug;9(4):1599-1605. doi: 10.21037/tlcr-20-617.

Hormone gene signature guides a novel therapeutic opportunity to improve 
sensitivity to HER family inhibition in lung cancer.

Yochum ZA(1)(2), Stabile LP(3).

Author information:
(1)Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer 
Center, Pittsburgh, PA, USA.
(2)Medical Scientist Training Program, University of Pittsburgh School of 
Medicine, Pittsburgh, PA, USA.
(3)Department of Pharmacology & Chemical Biology, University of Pittsburgh 
School of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Comment on
    J Thorac Oncol. 2020 Jan;15(1):62-79. doi: 10.1016/j.jtho.2019.09.195.

DOI: 10.21037/tlcr-20-617
PMCID: PMC7481617
PMID: 32953532

Conflict of interest statement: Conflicts of Interest: Both authors have 
completed the ICMJE uniform disclosure from (available at 
http://dx.doi.org/10.21037/tlcr-20-617). The authors have no conflicts of 
interests to declare.